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Abstract
Background: Factors affecting the efficacy of platelet and red blood cell (RBC) transfusion in patients undergoing
hematopoietic stem cell transplantation (HSCT) have not been studied extensively. We aimed to evaluate platelet and RBC
transfusion efficacy by measuring the platelet corrected count increment and the hemoglobin increment, respectively, 24 h
after transfusion in 105 patients who received HSCT.
Methodology/Principal Findings: Using retrospective analysis, we studied whether factors, including gender, time of
transplantation, the compatibility of ABO group between HSC donors and recipients, and autologous or allogenic
transplantation, influence the efficacy of blood component transfusion. We found that the infection rate of HSCT patients
positively correlated with the transfusion amount, and the length of stay in the laminar flow room was associated with
transfusion. We found that platelet transfusion performed during HSCT showed significantly better efficacy than that
performed before HSCT. The effect of platelet transfusion in auto-transplantation was significantly better than that in allo-
transplantation. The efficacy of RBC transfusion during HSCT was significantly lower than that performed before HSCT. The
efficacy of RBC transfusion in auto-transplantation was significantly higher than that in allo-transplantation. Allo-
transplantation patients who received HSCs from compatible ABO groups showed significantly higher efficacy during both
platelet and RBC transfusion.
Conclusions: We conclude that the efficacy of platelet and RBC transfusions does not correlate with the gender of patients,
while it significantly correlates with the time of transplantation, type of transplantation, and ABO compatibility between
HSC donors and recipients. During HSCT, the infection rate of patients positively correlates with the transfusion amount of
RBCs and platelets. The total volume of RBC units transfused positively correlates with the length of the patients’ stay in the
laminar flow room.
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Introduction
Hematopoietic stem cell transplantation (HSCT) refers to a type
of transplantation in which the patient is pretreated with total
body irradiation (TBI), chemotherapy, and immunosuppressive
pre-therapy followed by the transfusion of HSCs from normal
donors or from the patient himself/herself through blood vessels
[1]. Transfused HSCs possess the ability to proliferate, differen-
tiate into functional mature blood cells, and retain their self-
renewal capability. Hence, it can help patients rebuild normal
hematopoietic and immune function [2,3]. Based on whether
HSCs come from healthy donors or the patient himself/herself,
HSCT can be categorized into allogeneic (allo-) and autologous
(auto-) HSCT [4]. After allo-HSCT, due to various reasons (such
as chemotherapy and cell quiescent state), the platelet count and
hemoglobin (Hb) value decreases, and transfusion of platelets and
red blood cells (RBCs) in large amounts is needed [5]. Platelet
transfusion is an effective method for treating different bleedings
that are caused by reduced platelet [6,7]. RBC transfusion can
increase Hb levels and correct anemia [8–10]. Although the need
for blood component transfusion in HSCT patients has increased
rapidly, the guideline or strategy for clinical blood component
transfusion practices in patients with HSCT remains unclear. It is
unclear whether more amounts of transfusion would be better for
HSCT patients. It is unclear whether transfusion would increase
the infection rate in HSCT patients. It is unclear whether the
length of HSCT patients’ stay in the lamina flow room would be
affected by transfusion, and it is also unclear whether the
compatibility of HSCs would have some effect on the transfused
RBCs and platelets. Factors that influence the efficacy of blood
component transfusion during HSCT and the role of blood
transfusion in clinical outcomes in patients undergoing HSCT
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36912remains poorly understood. The aim of this study is to gain more
insight and knowledge about blood component transfusion
practices in populations undergoing HSCT.
Results
Efficacy of Platelet Transfusion in Patients Following
HSCT
Among the 105 patients, the efficacy of platelet transfusion in
male and female HSCT patients was 72.47% and 61.27%,
respectively, and gender did not correlate with the efficacy of
platelet transfusion (t=1.844, p=0.066, Figure 1 A and 1 B).
Platelet transfusion during HSCT showed a significantly higher
efficacy (72.69%) than transfusion before HSCT (54.84%;
t=2.612, p=0.009, Figure 1 C and 1 D). The effect of platelet
transfusion during auto-transplantation was significantly better
than that during allo-transplantation (86.52% vs. 63.77%,
t=3.102, p=0.002, Figure 1 E and 1 F). The effect of platelet
transfusion in recipients who received compatible HSCs was better
than that in recipients who received incompatible HSCs (74.29%
vs. 52.94%, t=2.034, p=0.044, Figure 1 G and 1 H).
Efficacy of RBC Transfusion in Patients Following HSCT
Among the 105 patients, the efficacy of RBC transfusion ranged
29.09–71.21%. The gender of the patients did not correlate with
the efficacy of RBC transduction (49.18% vs. 56.25%, p=0.684,
Figure 2 A and 2 B). The effect of RBC transfusion during HSCT
was significantly lower than that before HSCT (38.71% vs.
71.21%, p=0.035, Figure 2 C and 2 D). The effect of RBC
transfusion during auto-transplantation was significantly better
than that during allo-transplantation (41.94% vs. 37.63%,
p,0.001, Figure 2 E and 2 F). The effect of RBC transfusion
when the HSC donor and recipient had the same blood type was
better than when they had different blood types (50.00% vs.
29.09%, p=0.044, Figure 2 G and 2 H).
Relationship Between Infection Rate and Transfusion
The average volume of platelet units transfused in patients who
had infections during HSCT was greater than that in patients who
had no infection during HSCT (4.431 U vs. 3.045 U), and we
found that the total volume of platelet units transfused positively
correlated with the infection rate (R
2=0.288, p,0.05). The
average volume of RBC units transfused in patients who had
infections during HSCT was also greater than that in patients who
had no infection (4.000 U vs. 2.328 U). The total volume of RBC
units transfused also positively correlated with the infection rate
(R
2=0.247, p,0.05, Figure 3).
Relationship Between Factors and the Length of Patients’
Stay in the Laminar Flow Room
Regression analysis showed that during HSCT, the total volume
of RBC units transfused positively correlated with the length of the
patients’ stay in the laminar flow room (R
2=0.244, F=32.641,
p,0.001), whereas the volume of RBC units transfused and the
number and total amount of platelets transfused did not correlate
with the length of patients’ stay in the laminar flow room.
In addition, we also investigated the relation among the efficacy
of RBC transfusion, age, major diseases, and graft-versus-host
disease (GVHD). Using rank analysis, we found that these 3 factors
did not correlate with the efficacy of RBC transfusion (R
2=0.153,
p=0.090; R
2=0.064, p=0.481; and R
2=0.137, p=0.130,
respectively). Major diseases correlated with platelet transfusion
(R
2=0.169, p,0.05), but age and GVHD did not correlate with
platelet transfusion (R
2=0.090, p=0.179 and R
2=0.067,
p=0.312, respectively).
Discussion
In this study, we found that the efficacy of platelet transfusion
during HSCT and in patients with auto-transplantation and
matched ABO blood type between HSC donors and recipients
was significantly higher than that of transfusion before HSCT and
in patients with allo-transplantation and unmatched ABO blood
type, respectively. The RBC transfusion was more effective when
it was performed before HSCT and in patients with auto-
transplantation and matched ABO blood type between HSC
donors and recipients. Also, the infection rate in HSCT patients
positively correlated with the average transfusion amount, and the
total volume of RBC units transfused positively correlated with the
length of the patients’ stay in the laminar flow room, whereas the
number of RBC units transfused and the number and total
amount of platelet transfusion were not correlated. These data
provide guidance for future blood component transfusion practices
in HSCT patients.
Evaluating the Effect of Platelet Transfusion in HSCT
Patients
Platelet transfusion is an effective method for treating bleeding
caused by platelet decrement or platelet function deficiency and
can reduce death rate caused by bleeding due to platelet decrease
after radiation therapy or chemotherapy [11,12]. The currently
used apheresis platelet from a single donor not only decreases the
danger of transmitting blood-borne diseases and the chance of
homoimmune reaction, but also has homogeneous immunological
characteristics. Clinically, the demand for apheresis platelet from a
single donor is increasing every year. However, until now there
have not been well-accepted specific standards for evaluating its
clinical application in patients with HSCT. In some patients,
expected results were not achieved after platelet transfusion, and
after repeated transfusion, the efficacy of platelet transfusion
significantly reduced. Previous reports have shown that ineffective
platelet transfusion was 30–70% [13,14].
Factors that influence platelet transfusion include non-immu-
nologic factors such as platelet quality, infection, disseminated
intravascular coagulation, bone marrow transplantation, and
splenomegalia and immunologic factors such as repeated platelet
transfusion that causes the production of human leukocyte antigen
(HLA)-I and human platelet antigen (HPA) antibodies [15,16].
Afterward, more platelet transfusion leads to an antigen-antibody
reaction and damages the transfused platelets, which decreases the
platelet count and might result in symptoms such as chills and
fever [17,18]. In this study, during HSCT, the patients repeatedly
received platelet transfusion, and the number of platelet transfu-
sions received was many times more than that before HSCT.
Theoretically, the efficiency of platelet transfusion during HSCT
should not be as good as that before HSCT, while the results
showed an opposite outcome (see Table 1). This might be related
to the pretreatments during the preparation for HSCT. To
minimize graft rejection after HSCT, immune functions were
suppressed in the recipients by pretreatments involving TBI and
administration of cytotoxic drugs and immunosuppressors.
Immunosuppression weakens phagocytic function of the spleen
that eliminates transfused platelets and causes ineffective platelet
transfusion, especially in patients with splenomegalia. In this study,
all patients who received HSCT had pretreatments with immu-
nosuppressives, and this might explain the high efficacy of platelet
Factors in Efficacy of Transfusion
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36912Figure 1. Influential factors of the effect of platelet transfusion in patients with HSCT. We investigated factors influencing the effect of
platelet transfusion, including gender (A, B), the time of transplantation (C, D), auto-transplantation and allo-transplantation (E, F), and compatibility
of blood types the between recipients and donors (G, H). The error bar represents standard deviation. The results are shown as mean 6 S.D.
doi:10.1371/journal.pone.0036912.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36912Figure 2. Influential factors of the effect of RBC transfusion in patients with HSCT. We investigated factors influencing the effect of RBC
transfusion, including gender (A, B), the time of transplantation (C, D), auto-transplantation and allo-transplantation (E, F), and compatibility of blood
types between the recipients and donors (G, H). The error bar represents standard deviation. The results are shown as mean 6 S.D.
doi:10.1371/journal.pone.0036912.g002
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transfusion.
In this study, we also observed that ABO compatibility between
HSC donors and recipients correlated with efficacy of platelet
transfusion. The blood-type incompatibility in transplantation
could be a major ABO incompatibility, minor ABO incompati-
bility, or both. Transfusion of a small amount of RBCs mixed with
platelets (there are ABH antigens on the surface of platelets) in
HSCT patients receiving incompatible ABO blood type could
increase the ineffective rate [19]. Marktel et al. [20] found that
76% successful platelet transfusions were obtained in HLA-
matched and ABO-compatible patients followed by 67% in
HLA-1-mismatched and ABO-compatible patients or HLA-
matched and ABO-incompatible patients and by 46% in HLA-
1-mismatched and ABO-incompatible patients. Our observation
was consistent with this report. Therefore, compatibility of ABO
blood types between HSC donors and recipients is very important
for platelet transfusion in patients receiving HSCT, and the
potential acute hemolytic transfusion reaction should be closely
monitored.
Evaluating the Effect of RBC Transfusion in HSCT Patients
RBC transfusion increases Hb concentration and alleviates the
oxygen-deficient condition of the organism. Our data showed that
the overall efficacy of RBC transfusion in HSCT patients was
52.29%, which was lower than the efficacy of RBC transfusion
reported in literature. There might be 2 reasons for this low
efficacy of RBC transfusion in HSCT patients. First, most of the
transfusion occurred after HSCT with an average efficacy of
38.71%, which is much lower than that before HSCT (71.21%;
Table 2). The efficacy of RBC transfusion before HSCT was still
very close to the 80% reported in literature. Secondly, within some
time after HSCT, the original hematopoietic system of the patients
was destroyed, while the new grafted hematopoietic system was
not functional; therefore, the effect of RBC transfusion during this
period was worse than that before HSCT.
In this study, we found that ABO blood-type compatibility
between the HSC donor and recipient significantly correlated with
RBC transfusion efficacy. When allo-HSCT patients receive RBC
transfusion from a major ABO incompatible blood source, the
rebuild of the erythroid system was found to be slow [21,22].
However, the incidence rate of GVHD was not significantly
affected [23]. In about 15–30% of all the allo-HSCTs, the HLA
types but not the ABO blood types of the donor and recipient were
compatible [24,25]. Although it had been recommended early that
HSCT should not be performed using ABO incompatible donors,
it was shown later that the ABO blood-type system is not an
important transplantation antigen system. The ABO-blood type
compatibility did not significantly correlate with the successful
grafting of HSC, graft rejection, or survival of the patients, nor did
it substantially affect the incidence and severity of GVHD.
Therefore, the ABO blood type is not a contraindication of
HSCT. However, ABO blood-type incompatibility of the donor
and HSCT recipient may lead to severe platelet transfusion
refractoriness (PTR) [26]. Consequently, during HSCT, the HSC
suspension or the recipient should be processed properly, and
attention should be paid to blood transfusion after transplantation.
Clinical practice of over 20 years has shown that with an
appropriate approach, allo-HSCT can be successfully performed
despite ABO blood-type incompatibility. In allo-bone marrow
transplantation with ABO blood-type incompatibility, procedures
that decrease antibody titer of the recipient to the donor blood-
type antigen should be carried out to avoid acute hemolytic
transfusion reaction; however, in this type of transplantation, large
amounts of RBC transfusion is needed, and the restoration of the
erythroid system is slow [27]. Hence, blood component transfusion
will be more important in patients following the ABO-incompat-
ible donor’s HSCT. Compared to bone marrow transplantation,
Figure 3. The average volume of platelet and RBC units transfused in patients with or without infections during HSCT. The total
volume of platelet and RBC units transfused both positively correlated with the infection rate. The error bar represents standard deviation. The results
are shown as mean 6 S.D.
doi:10.1371/journal.pone.0036912.g003
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It has been considered that even in the presence of anti-donor
antibody, large amounts of erythroid progenitors in the peripheral
blood grafts may promote restoration of the erythroid system, and
ABO blood-type incompatibility does not affect the successful
grafting of allo-HSCT and prognosis [28].
Based on previous results, we have noticed that transfusion of
RBCs and platelets was greater in infected patients than in
uninfected patients undergoing HSCT. Due to immune dysfunc-
tion after HSCT, cytomegalovirus-specific cytotoxic T cells and T
helper cells do not respond effectively, and they cannot clear the
infection and generate immune protection, resulting in latent in
vivo viral recrudescence or cytomegalovirus infection through
transfused cells. In clinical practice, if we are free to raise the
transfusion threshold and use blood products excessively of
patients, especially during HSCT, they will be exposed to a high
risk of infection [29,30] The length of patients’ stay in a laminar
flow room increases with the number of total units of the RBC
received. This may be explained by the fact that the increase in
transfusion amount also raises the chances of infection or other
diseases.
Our results also have showed that factors such as age, major
diseases, and GVHD do not correlate with the efficacy of RBC
transfusion. However, the efficacy of platelet transfusion correlated
with the disease diagnosed when the patient was admitted for
transfusion. This correlation may be explained by the fact that the
damage caused by major diseases to hematopoiesis and immune
function is different. After HSCT and chemotherapy, the recovery
of the megakaryocyte system in patients is often slower than that of
the RBC system, and the recovery of immune function is also
slower than that of hematopoietic function.
Transfusable RBC and Platelet Blood Types When the
Blood Types of the Donor and the Recipient were
Different During Peripheral HSCT
As the immune function is suppressed and the hematopoietic
function is rebuilt in patients after HSCT, the effects of platelet
and RBC transfusion are substantially different from those before
Table 1. Efficacy of platelet transfusion in105 patients following HSCT.
Number of
transfusion
Number of effective
transfusion Efficacy (%)
Gender Male 178 129 72.47 t=1.844, p=0.066
Female 142 87 61.27
Time of transfusion Before transplantation 93 51 54.84** t=2.612, p=0.009
During transplantation 227 165 72.69
Type of transplantation Auto-transplantation 89 77 86.52** t=3.102, p=0.002
Allo-transplantation 138 88 63.77
Blood types of donor
and recipient
Same 70 52 74.29* t=2.034, p=0.044
Different 68 36 52.94
Note: The ‘‘effective transfusion’’ refers to those with CCI$4.500 24 h after transfusion; number of units transfused Plt1U/transfusion;
*p,0.05;
**p,0.01;
***p,0.0001.
doi:10.1371/journal.pone.0036912.t001
Table 2. Efficacy of red blood cell transfusion in 105 patients following HSCT.
Number of
transfusion
Number of effective
transfusion Efficacy (%)
Gender Male 122 60 49.18 F=0. 167, P=0.684
Female 96 54 56.25
Time of transfusion Before transplantation 94 66 71.21* F=4.512, P=0.035
During transplantation 124 48 38.71
Type of transplantation Auto-transplantation 31 13 41.94*** F=20.307,
P,0.001
Allo-transplantation 93 35 37.63
Blood types of
donor and recipient
Same 38 19 50.00* F=4.155, P=0.044
Different 55 16 29.09
Note: The ‘‘effective transfusion’’ refers to those with Hb elevated by 10 g 24 h after transfusion of 2U red cell suspension;
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0036912.t002
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transfusion only based on the value calculated from the formulas
for Charlson Comorbidity Index (CCI), percentage of platelet
recovery, and Hb increment. Rather, it might be of more clinical
significance to evaluate the transfusion effect based on a
combination of values and other clinical outcomes of the patients
after transfusion, and this question will need further study.
Optimal use of Blood Components Requires More
Attention
A declining donation rate and an increase in the consumption of
blood components require improved approaches on the blood
supply chain. Complex therapeutic procedures like HSCT may
require intensive blood component support, which leads to a
steady increase in the consumption of standard blood components,
while blood component transfusions are critical for recovery in
patients receiving HSCT. Therefore, alternative strategies that
improve transfusion efficiency will decrease the blood product
consumption per individual procedure.
As RBC antigen is a natural antibody, the transfusion efficacy
might decrease when an incompatible ABO blood type is used for
transfusion [31]. We propose to use transfusable, washed blood
type O (Table 2) to reduce the demand for RBC transfusion and
the risk of transfusion-transmitted disease and ensure the support
of oxygen in tissues during the HSCT. It might also decrease the
total amount of transfused RBCs during transplantation as well as
the length of stay in the laminar flow room.
During HSCT, immune function in patients is suppressed and
immune-related platelet transfusion is more efficient. So, in
combination with clinical manifestations, the threshold for platelet
transfusion can be reduced from 20610
9/L to 10610
9/L or even
less, which could save blood for transfusion, relieve the pressure on
blood supply, decrease the financial burden of patients, and ensure
clinical efficacy at the same time.
In summary, our data have shown a relationship between the
clinical outcome of the blood component transfusion and factors
that affect the efficacy of blood component transfusion. A sound
clinical transfusion plan is needed not only to reduce the blood
product consumption, but also to reduce the risk of infections.
Materials and Methods
Subjects
A total of 105 patients were randomly selected from among
patients who were admitted to the Hematology Department of the
Xinqiao Hospital affiliated to the Third Military Medical
University (Chong Qing, China) between January 1, 2006, and
August 31, 2010. These patients suffered from platelet decrease
and anemia before HSCT (day 260–day 0) and during HSCT
(day 0–day 52). Patient and HSCT characteristics are summarized
in Table 3. Written informed consent was obtained from each
patient, and this study was approved by the ethics committee of
the Xinqiao Affiliated Hospital of the Third Military Medical
University of Chinese of the People’s Liberation Army (PLA).
Equipment and Blood Components
BC-5500 and BC-5300 hematology analyzers (Mindray Inc.),
XT 1800i and SE-9000 hematology analyzers (Sysmex), CS-3000
plus blood cell separator (Baxter), and Fresenius COM.TEC blood
cell separator (Fresenius) were used in this study. Apheresis
platelets and RBC suspensions were provided by the Chongqing
Blood Center.
Evaluation Standards for the Effect of Blood Component
Transfusion
Platelets. Platelet corrected count increment (CCI) =
platelet increment (PI, 10
9/L)6body surface area of the recipient
(BSA; m
2)/total number of transfused platelets (10
11/L). The BSA
of the recipient (m
2)=0.00616height (cm) +0.01286weight (kg)
2 0.01529. For 1 U, the number of single donor platelets was
2.5610
11/bag, and it is same for all the formulas given below [2].
The platelet transfusion was considered ineffective if CCI ,7.5
1 h after the transfusion and ,4.5 20–24 h after transfusion. Due
to limited condition, very few patients in our study were tested for
CCI 1 h after platelet transfusion; hence, the evaluations were all
based on CCI 24 h after transfusion [32,33]. We investigated the
impact of several factors, including gender, time of transfusion
following HSCT, auto- or allo-transplantation, and ABO blood-
Table 3. Patients and HSCT characteristics.
Number of
patients %
Gender
Male 62 59.05
Female 43 40.95
Donor type
Auto-transplantation 41 39.051
Allo-transplantation 64 60.95
ABO groups of HSC donors and
recipients
Match 38 59.38
Mismatch 26 40.62
Main complications
Bleeding gums 8 7.62
Canker sore and nasal cavity bleeding 40 38.10
Petechial hemorrhage spots on the skin 22 20.95
Gastrointestinal bleeding
infected patients
7
36
6.67
34.29
Primary diagnosis
Acute lymphoblastic leukemia 13 12.38
Acute non-lymphocytic leukemia 24 22.86
Chronic myelocytic leukemia 18 17.14
Aplastic anemia 3 2.86
Thrombopenic purpura 3 2.86
Non-Hodgkin’s lymphoma 20 19.05
Hodgkin’s lymphoma 4 3.81
Lymphoma leukemia 6 5.71
Multiple myeloma 3 2.86
Neuroendocrine tumor 1 0.95
Hybrid acute leukemia 2 1.90
Myeloproliferative disease 3 2.86
Systemic lupus erythematosus 2 1.90
Hand-schu ¨ller-christian disease 1 0.95
Anaplastic large-cell lymphoma 1 0.95
Primary macroglobulinemia 1 0.95
Median Age at HCT (range), years 33 (3,68)
Total number 105
doi:10.1371/journal.pone.0036912.t003
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efficacy of platelet transfusion. Patients underwent transfusion if
their platelet threshold was 10610
9/L [34,35] or if they had severe
bleeding.
RBCs. To evaluate the effect of RBC transfusion, we
considered 3 standards, including RBC count, hematocrit (Hct),
and Hb. As the main purpose of RBC transfusion is to elevate Hb
to carry more oxygen, the most important index for calculating the
clinical effect of RBC transfusion is Hb increment in circulating
blood. The other 2 factors are often used as references. In general,
24 h after transfusion of 2 U (400 mL) of RBC suspension, the Hb
level increases by 10 g/L. The RBC transfusion was considered
ineffective if Hb increment was lower than 10 g/L. According to
the ‘Technical Guide for Clinical Transfusion’ in China, we
performed transfusion if a patient had Hb ,60 g/L or had
symptoms such as severe bleeding or anemia.
For incompatible ABO blood type between HSC donors and
recipients, the blood type of transfusable washed RBCs and
platelets was according to transfusion compatibility chart (Table 4).
Statistical Analysis
Statistical Package for the Social Sciences (SPSS) 18.0 software
was used for statistical analysis. Student’s t-test was performed to
analyze the significance of the efficacy of platelet transfusion.
Repeated measures analysis of variance was performed to analyze
the significance of the efficacy of RBC transfusion. Spearman’s
rank correlation analysis was used to analyze the relationship
between the infection rate and the total amount of platelet and
RBC transfusion during HSCT. Multiple regression (stepwise
method) was adopted for statistical analysis of the relation among
the number and total amount of RBC and platelet transfusion, Hb
concentration at the first transfusion, and the patient’s length of
stay in the laminar flow room. Results with p,0.05 were
considered statistically significant.
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